Meds, Mind, Body & Benefits > Research News & Studies

OTHER BREAKTHROUGHS IN HIV SCIENCE

(1/1)

bimazek:
OTHER BREAKTHROUGHS IN HIV SCIENCE     
     
Maraviroc remains on track for a new drug in treatment-experienced patients by year-end 2006. The compound blocks entry of HIV virus into cells by binding to the CCR5 co-receptor.

               

Another breakthrough in HIV Science which won the Noble prize in October 2006 by two young scientists
out of Stanford, called RNA interference, RNAi, has emerged as an effective way to block the specific messenger
RNAs in human cells. Using this approach, it has proven possible to block the replication
of HIV-1 in cells using small interfering RNAs targeted to viral sequences or to messenger
RNAs that encode factors critical for virus replication.  What about HIVs ability to mutate?
This problem may be circumvented by simultaneously targeting several essential HIV-1 sequences using RNA interference.

         
         
     
     
Merck has just purchased the rights for PPL-100 HIV protease inhibitor, for $215 million, from the Biotech company,  Ambrilia based in Quebec U.S. as the product moves through trials to a target market launch in 2011.  "This is the breakthrough that will transform our company," said Ambrilia CEO Hans Mader. "This drug can help fight the HIV virus and lengthen lives."    Merck, itself a leading developer of HIV/AIDS drugs, takes over development of Ambrilia's PPL-100 when certain Phase I trials are completed in November. Technically, PPL-100 is an HIV protease inhibitor,
     

A Southern California based biotech company, Immune Response said "With guidelines recommending delayed intervention for newly diagnosed HIV patients based on CD4 and viral load counts, an immune-based therapy like REMUNE® that could possibly delay initiation of antiretroviral therapy would be an important advance in the treatment of HIV."   Also another medicine IR103 for HIV/AIDS studies indicate that a patient's CD4+ count is the
most significant marker of HIV disease progression. An immune based therapy
like IR103 that can impact CD4+ count may well be an enormous contribution
to the current treatment landscape.   an article from this month's issue of
Scientific American called "Peacekeepers of the Immune System" which
details the role of FoxP3+ T Regulatory cells, the same cells our product,
NeuroVax(TM) has been shown to stimulate, HIV/AIDS -- IR103,
HIV/AIDS community are beginning to
understand that the "whole, inactivated" HIV antigen concept -- our
technology -- has not been explored enough either as a therapeutic or
preventive vaccine.




merck: MK-0518, an investigational oral HIV integrase inhibitor   Tolerability of MK-0518 was comparable to placebo plus greater antiretroviral suppression was maintained, in HIV-infected patients who failed antiretroviral therapy and who were resistant to drugs in all three classes Show That Over 90% of Patients Achieve Treatment Goal of Undetectable Viral Load.
Exciting new clinical data demonstrate that 90 to 95 percent HIV patients who initiate therapy with FUZEON(R) (enfuvirtide) and the investigational integrase inhibitor MK-0518 can achieve undetectable levels of HIV

Navigation

[0] Message Index

Go to full version